NKP-1339

structure in first source

Also Known As:

RuCl4(1H-indazole)2

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Neoplasms (Cancer) 01/01/2017 - "The Ru-based anticancer drug NKP-1339 was studied applying XANES (Cl K- and Ru L2,3-edges) in tumor, kidney and liver tissue of a SW480 bearing mouse. " 01/01/2016 - "The enhanced permeability and retention (EPR) effect, which is diversely being exploited for tumor targeting, could therefore be applicable for NKP-1339. "
2.	Carcinoma (Carcinomatosis) 01/01/2016 - "Molecular mode of action of NKP-1339 - a clinically investigated ruthenium-based drug - involves ER- and ROS-related effects in colon carcinoma cell lines."

1.	Ruthenium